39. Are there new treatments on the horizon for treatment of chronic hepatitis B?
The other thing to be encouraged about, is
that hepatitis B is actually a rich area of ongoing studies. These are
abbreviations of drugs that are in various stages of study. Entecavir, that will be out by Bristol Myers
Squibb will probably be on the market in about a year or a year and a
half, it’s in the latest stages of study. They all have different
characteristics. What encourages me is that some of my
patients, when they have e-Negative chronic hepatitis B, we say we’re
going to start adefovir and you’re going to have to take this for a
long time, that creates an anxiety because there will be a certain
amount of resistance. But I know that lamivudine is effective
against the A181V mutation and I suspect that some of these agents
will also be active against other mutations. So the bottom line is that we’re going to
have a whole shelf-full of drugs over the next five years, and
probably more use of interferon, so that there will be lots of
treatment options as we go down the road.
38. What are the advantages and disadvantages of the current approved hepatitis B treatments?
You have completed this presentation.
Please give us your opinion by filling out our feedback form.